Medicenna Therapeutics Corp

Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. It engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medicenna Therapeutics Corp. (MDNA) CEO Fahar Merchant on Q1 2022 Results - Earnings Call Transcript

-- Phase 1/2 ABILITY Study of MDNA11 in patients with advanced solid tumors remains on track for initiation in the third quarter of calendar 2021

Medicenna Reports First Quarter Fiscal 2022 Financial Results and Operational Highlights

TORONTO and HOUSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on August 13, 2021 at 8:30 AM ET to report its first quarter fiscal 2022 financial results and operational highlights.

Medicenna to Announce First Quarter Fiscal 2022 Financial Results and Operational Highlights on Friday, August 13, 2021

-  Phase 1/2 ABILITY Study is designed to evaluate MDNA11, a potentially best-in-class IL-2 Superkine, in patients with advanced solid tumors

Medicenna Announces That Initiation of MDNA11 Phase 1/2 Study is on Track; Update to be Provided at the PropThink Digital Conference

-- Preclinical results in a pancreatic cancer model show that MDNA109, delivered by an oncolytic adenovirus, induced superior anti-tumor response with tendency towards complete tumor regression, improved survival, and long-term immune memory effect

Medicenna's IL-2 Superkine Platform Featured in Peer-Reviewed Publication Demonstrating its Superiority and Ability to Reprogram the Tumor Microenvironment in Pancreatic Cancer

-- Initiation of the ABILITY Study, a first-in-human trial, is expected in the third quarter of 2021

Medicenna Announces Submission of Clinical Trial Application in Australia for a Phase 1/2 Study of MDNA11

Medicenna Therapeutics Corp.'s (MDNA) CEO Dr. Fahar Merchant on Q4 2021 Results - Earnings Call Transcript

-- Management hosting conference call and webcast today at 8:30 AM ET

Medicenna Reports Fiscal Year 2021 Financial Results and Operational Highlights

TORONTO and HOUSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the appointment of Mann Muhsin, MD, as the Company's Chief Medical Officer.

Medicenna Appoints Immuno-Oncology Expert Dr. Mann Muhsin as Chief Medical Officer

-- Data published in Clinical Cancer Research indicate that early determination of PFS with modified RANO criteria may be a strong surrogate for overall survival in recurrent glioblastoma

Medicenna Announces the Peer-Reviewed Publication of Clinical Data from Phase 2b Trial Evaluating MDNA55 in Recurrent Glioblastoma

TORONTO and HOUSTON, April 21, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the appointment of Kevin Moulder, PhD, as the Company's Chief Scientific Officer (CSO).

Medicenna Therapeutics Announces the Appointment of Industry Veteran, Kevin Moulder, PhD, as Chief Scientific Officer

TORONTO and HOUSTON, April 14, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will present a corporate overview at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20th, 2021, at 10:00 AM ET.

Medicenna to Present at the Bloom Burton & Co. Healthcare Investor Conference

-- The IL-2/IL-13 dual specific cytokine selectively stimulates anti-cancer immune cells and inhibits M2a polarization of pro-tumoral macrophages

Medicenna Presents Preclinical Data Demonstrating Potent Immune Modulating Effects of an IL-2/IL-13 Dual Specific Cytokine at the 2021 AACR Annual Meeting

-- MDNA11 and anti-PD-1 combination leads to complete responses in a murine solid tumor model

Medicenna Announces Preclinical Data on MDNA11 with Anti-PD-1 Therapy and Unveils Novel Bifunctional Superkines at the Cytokine-Based Cancer Immunotherapies Summit

TORONTO and HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will be presenting at the H.C. Wainwright Global Life Sciences Conference and at the Oppenheimer 31st Annual Healthcare Conference, as well as participating in a live panel discussion at the Maxim 2021 Emerging Growth Virtual Conference. All three virtual investor conferences will take place in March 2021.

Medicenna Therapeutics to Present at Upcoming March Investor Conferences

TORONTO and HOUSTON, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will present a corporate overview at the 41ST Annual Cowen Healthcare Conference on Tuesday, March 2, 2021, at 2:10 PM ET.

Medicenna to Present at the Cowen 41st Annual Healthcare Conference

TORONTO and HOUSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will present a corporate overview at the 10th Annual Leerink Global Healthcare Conference on Friday, February 26th, 2021, at 3:00 PM ET.

Medicenna to Present at the 10th Annual SVB Leerink Global Healthcare Conference

TORONTO and HOUSTON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “Company") (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quarter ended December 31, 2020. All dollar amounts are expressed in Canadian currency unless otherwise noted.

News for Medicenna Therapeutics Corp Stock (MDNA)